Recent work confirms a bench-to-bedside approach that circulating tumor DNA is associated with outcome and objective response to chemotherapy in patients with advanced leiomyosarcoma. Liquid biopsies may be used for risk stratification in future trials guiding treatment decisions by identifying patients who are likely to benefit from chemotherapy. See related article by Madanat-Harjuoja et al., p. 2579. ©2022 American Association for Cancer Research.
Bernd Kasper, Breelyn A Wilky. Sounding the Alarm on Leiomyosarcoma Recurrence: Role of Circulating Tumor DNA. Clinical cancer research : an official journal of the American Association for Cancer Research. 2022 Jun 13;28(12):2480-2481
PMID: 35412607
View Full Text